Roche terminates phase 1 trial of RO7763505 in coronary artery disease
The study, which was testing the drug in healthy volunteers and stable CAD patients, was stopped with Roche citing discontinued development.
Hoffmann-La Roche has terminated a Phase I study of its investigational drug RO7763505, according to a record on ClinicalTrials.gov. The trial's status is listed as terminated, with the reason given as: The development of RO7763505 for coronary artery disease has been discontinued.1
The study was registered under NCT07495813, with sponsor study ID BP46355. It was designed as a Phase I, randomized, double-blind, adaptive, placebo-controlled, single-ascending dose and multiple-ascending dose, parallel study examining safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of RO7763505 given orally to healthy participants and patients with stable coronary artery disease.1
According to the registry, the study start date was listed as March 31, 2026, with primary completion and study completion both recorded as August 20, 2026.1 The record was first posted on March 27, 2026, and last updated on November 17, 2026.1
The trial design included single ascending doses in Part 1a, multiple ascending doses in Part 1b, and a food effect assessment in Part 1c, all in healthy adult participants, followed by a Part 2 evaluating multiple doses in participants with stable coronary artery disease.1
Despite the planned scope, enrollment at termination totaled 39 participants actual, in a trial with triple masking covering participant, care provider, and investigator.1 The study was conducted at a single site: ICON Plc (LPRA) in Groningen, Netherlands.1
The registry does not state why Roche decided to discontinue development of RO7763505 for coronary artery disease, beyond the brief termination reason provided.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.